Cognition Therapeutics Secures $30 Million Funding for Trials
- The offering was made to two new fundamental institutional investors -
- The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders -
PURCHASE, N.Y. — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company specializing in the development of innovative drugs targeting neurodegenerative disorders, has announced a significant move to boost its financial resources. They have entered a securities purchase agreement for a registered direct offering, aiming to sell 14,700,000 shares of its common stock. This offering is set to generate gross proceeds of approximately $30 million, excluding placement agent fees and other related expenses.
The close of this offering is anticipated to take place shortly, around the end of August, as it is contingent upon meeting customary closing conditions. The funds will play a crucial role in supporting the next phases of their Phase 3 programs focusing on zervimesine, a promising candidate in the treatment of neurodegenerative disorders, as well as providing necessary working capital and covering general corporate purposes.
The offering has attracted the attention of two new fundamental institutional investors, including a reputable global investment firm, which underscores the growing confidence in Cognition Therapeutics and its mission.
Funding Utilization and Future Prospects
The net proceeds from this offering are particularly earmarked to solidify Cognition's preparations for their clinical trials of zervimesine. This drug has been engineered with a focus on treating conditions like Alzheimer's disease and other age-related cognitive decline. The Company’s approach to tackling these pressing health issues positions them as a front-runner in this critical area of medicine.
Cognition's innovative strategy lies in its commitment to using cutting-edge research and development techniques. By leveraging the funds from this offering, they aim to further their studies and enhance their capabilities in bringing zervimesine to market. Additionally, ongoing work in the Phase 2 studies of zervimesine demonstrates the Company's commitment to advancing treatments that target specific neurodegenerative mechanisms.
Role of Titan Partners Group
Titan Partners Group, a division of American Capital Partners, has taken on the role of the sole placement agent for this offering, ensuring that it aligns with Cognition's vision for growth and development. Their expertise in structuring such transactions is invaluable as Cognition navigates the complexities of funding stages.
Through this strategic offering, Cognition is not just securing financial backing but is also reinforcing its position within the biopharmaceutical industry. This funding allows further acceleration of their pipeline innovations which focus on disorders that significantly impact patients’ quality of life.
Insights into Cognition Therapeutics
Cognition Therapeutics, Inc. is recognized for its pioneering work in the field of age-related degenerative disorders, particularly those impacting the central nervous system. The Company is currently conducting Phase 2 studies of its lead candidate, zervimesine (CT1812), in a variety of conditions including dementia with Lewy bodies and mild-to-moderate Alzheimer’s disease.
The ongoing Phase 2 study, known as the START study, which targets early Alzheimer's disease, has gained momentum with significant financial backing from the National Institute on Aging at the National Institutes of Health, further highlighting the potential of zervimesine and the Company’s robust pipeline.
With its unique ability to interact with the sigma-2 receptor, zervimesine is believed to have potential advantages over existing treatment avenues. As Cognition Therapeutics advances its research, it remains committed to discovering novel therapies that could make a real difference in patients' lives.
Contact Information
For further inquiries, interested parties can reach out to Cognition Therapeutics at:
Cognition Therapeutics, Inc.
info@cogrx.com
Investors can also contact Mike Moyer at LifeSci Advisors via email at:
mmoyer@lifesciadvisors.com
Frequently Asked Questions
What is the purpose of the $30 million offering?
The funds from the offering will support preparations for Phase 3 trials of zervimesine and provide working capital for Cognition Therapeutics.
Who are the new investors involved in this offering?
The offering has attracted two new fundamental institutional investors, including a well-known global investment manager.
What is zervimesine?
Zervimesine is a drug candidate developed by Cognition Therapeutics aimed at treating neurodegenerative disorders such as Alzheimer’s disease.
How does Cognition Therapeutics plan to use the proceeds?
The net proceeds will be used for clinical trial preparations, general corporate purposes, and working capital needs.
Who can be contacted for more information?
For inquiries, you can contact Cognition Therapeutics via email at info@cogrx.com or reach Mike Moyer at mmoyer@lifesciadvisors.com.
